What is the current prevalence of Hereditary Haemorrhagic Telangiectasia (HHT) in the UK and how does it vary with respect to age, sex, socioeconomic status and geographical location?
INTRODUCTION
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant genetic disorder of blood vessel development characterised by mucocutaneous telangiectases and by arteriovenous malformations (AVMs) in solid organs [1, 2] . HHT is associated with significant morbidity due to bleeding complications such as epistaxis and gastrointestinal haemorrhage and from embolic complications including cerebral abscess and stroke [3] , which are often associated with pulmonary arteriovenous malformations (PAVMS) [4] . HHT may also be associated with reduced life expectancy [5, 6] .
HHT can be identified by clinical or genetic screening of family members of affected individuals but is too often diagnosed as a result of advanced complications of the disease. A recent expert panel has recommended screening all possible or confirmed HHT cases for PAVMs [7] . Population-based epidemiological studies in HHT are the essential first step in understanding and quantifying the burden of disease and informing healthcare planning for this under-recognised condition. There are few data regarding differences in geographical prevalence of HHT in the UK or associations with sex, age and socioeconomic status, and this is important as understanding these relations may increase knowledge of factors that modify both development and diagnosis of the disease.
Hence, the aim of this study was to determine, using a representative sample of the UK population obtained via an electronic general practice database, a contemporary prevalence of diagnosed HHT and its association with age, sex, geographical location and deprivation status.
METHODS

Study population
This study utilised an anonymised, computerised, longitudinal general practice database known as The Heath Improvement Network (THIN) which has been validated for epidemiological research [8, 9] . The THIN database records a variety of patient clinical and lifestyle data from consultations both in primary and secondary care including medical conditions, symptoms, medications and sociodemographic details. At the time of data extraction (September 2011), THIN covered 5% of the UK population with 3.46 million patients actively followed prospectively from 440 general practices [10] .
Definition of disease
We initially identified all recorded diagnoses (by medical Read codes) between the years 2000 and 2010 of Hereditary Haemorrhagic Telangiectasia (G770.00) and Rendu-OslerWeber Disease (G770.11). Given the high prevalence of HHT in individuals with pulmonary AVMs [11] we also searched for Read codes pertinent to pulmonary AVMs (we excluded any individuals previously identified as having Read codes for HHT or Rendu-Osler-Weber disease to prevent double-counting). Population denominator values were derived from the annual mid-year populations contributing to THIN. The results presented in this paper are for patients coded as Hereditary Haemorrhagic Telangiectasia (G770.00) or Rendu-OslerWeber Disease (G770.11) only. A repeat analysis of a wider population was conducted which included all the Read codes listed in Table 1 .
Statistical methods
Data for 2010 (the most recent complete data year) were used to calculate a point prevalence for HHT. We stratified our results by sex, age group (<15 years, 15-49 years and 50+ years), geographical location and socioeconomic status. Geographical location was defined by UK Health Authority areas and socioeconomic status was based on the Townsend index score in quintiles [12] . Given the relatively small numbers available for analysis by health authority in 2010, we used combined data from 2000-2010 to calculate prevalence estimates for HHT between different health authorities in the UK adjusting for the use of repeated measures (see below). We were able to look for any significant changes in the 
Overall Prevalence
The point prevalence of HHT in 2010 was 1.06 per 10,000 (95% CI: 0.95-1.17) or 1 per 9,400.
In the sensitivity analysis using broader diagnostic criteria (combining all Read codes from 
Prevalence by Sex and Year
The prevalence of a diagnosis of HHT was strongly related to sex, with a higher prevalence rate in females compared to males for all years between 2000 and 2010 (Fig 1) . In 2010 the point prevalence in women was 1.29 per 10,000 person years (95% CI: 1.12-1.46) and for men was 0.82 per 10,000 person years (95% CI: 0.69-96). After adjusting for age, deprivation status and geographical location, the prevalence rate ratio (PRR) in 2010 for HHT was higher in women compared with men (PRR 1.59, 95% CI: 1.30-1.94, p<0.0001). The prevalence rate for both men and women has remained relatively constant over the last 10 years.
Prevalence by Sex and Age group
Prevalent cases from 2010 were grouped into 3 different age categories (<15 years, 15-49 years and 50 years and over) and stratified by sex (Fig 2) . The unadjusted prevalence rate in both sexes was lowest in those aged <15 years and highest in the 50+ age group though the adjusted prevalence rate ratios across the age groups did not differ significantly (p test for trend =0.29) ( Table 2 ). Table 2 . Crude prevalence rates and prevalence rate ratios of HHT derived from Poisson regression modelling using The Health Improvement Network dataset in 2010.
*Adjusted for sex, age group, Townsend score and health authority ᵒp-trend across age categories
Prevalence by Deprivation status
The prevalence of HHT was inversely associated with socioeconomic deprivation ( Table 2 ).
The crude prevalence rate in the most deprived group (Townsend score: quintile 5) was 0.68 per 10,000 (95% CI: 0.43-0.93) compared to 1.31 per 10,000 in the least deprived quintile (95% CI: 1.07-1.55). After adjusting for the effects of age, gender and geographical location, the prevalence rate ratio was higher in those in the least deprived socioeconomic group when compared to those in the most deprived group (PRR 1.74, 95% CI: 1.14-2.64, p<0.0001).
Prevalence by Health Authority
There was substantial variation in estimates of the crude prevalence of HHT across the UK when stratified by health authority over the 10 year period 2000-2010 (Fig 3) . 
Sensitivity Analysis
The above analyses were repeated to include all Read codes listed in Table 1 , rather than those for HHT and Rendu-Osler-Weber Disease alone and revealed no significant differences in qualitative trends of our results nor significance values for these trends. There was a slight change in the prevalence rate ratios calculated for the different health authority areas in the sensitivity analysis, with HHT or PAVMs diagnosed most commonly in Yorkshire rather than the South West (data not shown).
DISCUSSION
Summary of results
This is the first study to use a national primary care population-based database to explore sex, socioeconomic and regional differences in the prevalence of hereditary haemorrhagic telangiectasia, as well as providing national prevalence figures for the United Kingdom. The 2010 point prevalence for HHT in the UK is 1.06 per 10,000 (or 1 per 9,400) which has remained relatively stable between 2000 and 2010. The prevalence estimate is higher when
Read codes likely to be associated with HHT are included (1 per 8,700) and is higher still if the prevalence in females is considered to be more representative of the population as a whole (1 per 7,800). The prevalence increases with age. The diagnosed prevalence ratio of HHT was 59% higher in women than in men and 74% higher in those from the least deprived socioeconomic group when compared to those in the most deprived group. In addition, we have demonstrated a substantial geographical variation in the diagnosed prevalence of HHT across the UK.
Strengths and Weaknesses
This is the first population-based study of HHT using a primary care database in the UK general population. With a total of 365 HHT prevalent cases identified in 2010 our study sample size is almost four times larger than the last UK estimate undertaken in 1992 [13] , is nationally representative and comparable in size with epidemiological studies conducted in other countries [6, 14, 15] . We have been able to stratify our prevalence estimates by sex, age group, deprivation status and geographical location without the risk of bias that may occur either from low response rates (as have been observed in previous surveys of HHT prevalence in the UK [13] ) or from case-series in specialist centres which may lack a denominator population or represent cases referred for specialist care with potentially more severe disease.
There are potential limitations to the study which should be addressed. The first is that of the validity of the HHT diagnoses, which are recorded by general practitioners in the THIN database whilst the clinical diagnosis is generally made in secondary care. In practice, we are reasonably confident that the vast majority of these diagnoses will be correct with the increasing involvement of clinical geneticists in the screening and diagnosis of HHT which should result in more reliable information being conveyed to the primary care practitioner, and hence entered into the database. It seems very unlikely that a primary care practitioner would enter a diagnosis of HHT into the database unless it was supported by correspondence from secondary care. The consistency of our calculated prevalence of HHT with other comparable estimates from previous studies also supports the reliability of our findings. One further limitation that complicates all studies of HHT prevalence at present is the likelihood of undiagnosed individuals with HHT at large in the community. This may explain the higher prevalence of PAVMs as defined by radiological criteria (and by inference, HHT) in patients who were participating in a recent Japanese CT screening program for lung cancer [16] than we observed in our dataset which did not use this radiological definition of the disease. Diagnosis is often confounded by the heterogeneous clinical presentation of HHT due to its variable genetic penetrance and expressivity [17] . An average time lag of 25 years separates disease onset and first definite diagnosis [18] . Hence, our prevalence estimates represent those with diagnosed HHT, and are likely to be lower than the true prevalence defined as all individuals with a mutation compatible with the disease. The fact that our data show the prevalence of the disease has been stable in both sexes over the last decade would suggest that the consistency in coding practice over this period has been maintained.
We used the Townsend score which is a deprivation index based on area as it was not possible to access individual-level deprivation data. This score presumes that individuals living within a geographical area have a similar deprivation status which may not be the case. However, there is evidence to suggest that the Townsend scores calculated at a district level are good proxy measures for individual levels of deprivation [19] .
Interpretation of results
Reasons for the marked sex difference between the diagnosed prevalence of HHT require careful consideration. One study from the Dutch Antilles showed a 33% increased prevalence ratio of a 'definite' diagnosis of HHT in females compared with males (using the Curacao criteria) [15] , and a recent US paper found a female:male ratio of 1.54, with HHT being diagnosed more commonly in females [20] . Other studies have reported a more balanced distribution between sexes [14, 17] . Given HHT is an autosomal dominant disorder, the offspring of affected individuals will have a 50% chance of inheriting a mutation and this should not per se be associated with a sex bias. Our data show a significant difference in diagnosis of HHT in women compared with men which appears to be greatest between the ages of 15 and 49. One possible explanation for this observation is that the higher diagnosed prevalence of HHT in females we observed is due to a difference in access to healthcare resources. Women have significantly higher rates of consultation with primary care
providers during the ages of 15 to 70 years with many consultations due to issues surrounding contraception, pregnancy and childcare, and this may explain an increased ascertainment of symptomatic females with HHT [21, 22] . A possible alternative explanation for the disparity between sexes may be that the expression of the HHT phenotype is more common in females with the gene mutation. Little is known about the role of other genetic factors (such as moderator genes) or environmental factors that may modify the HHT phenotype but there is limited evidence that symptoms such as epistaxis may be amenable to treatment via manipulation of oestrogen and progesterone levels [23] . During pregnancy there is an increased risk of developing complications of HHT [24, 25] and it has been suggested that this may represent a modification of the HHT vasculature by female hormones or be secondary to the haemodynamic changes of pregnancy. Clarifying whether the sex differential in diagnosis of HHT is due solely to behavioural factors or may be partly due to biological reasons is an important area for further research.
The reduced prevalence of diagnosed HHT in those from lower socioeconomic groups has multiple potential explanations which encompass controversial issues such as the proximity and quality of healthcare services provided in more deprived areas, as well as differentials in individuals' thresholds for accessing these services across different socioeconomic groups. It is internationally recognised that health and healthcare access inequities vary along social gradients [26] and one study looking at health seeking behaviour in those from more deprived areas with asthma found that these populations reported a higher prevalence of respiratory symptoms but had lower consultation rates for those symptoms [27] .
Explanations such as varying access to health care, differing perceptions of symptom severity or less positive views of health care services were postulated to explain this disparity [27, 28] . per 10,000 (or between 1 per 6,000 and 1 per 10,000) and our study estimate falls within this range, although data from individuals with health insurance in the USA provide estimates as low as 1 per 33,000 [20] . Our findings with respect to age are consistent with previous work with the prevalence of HHT being higher in older age groups, suggesting that the disease has an age-related penetrance [17] or alternatively that the likelihood of diagnosis is related to longevity. No other studies have looked at the prevalence of diagnosis by deprivation status and most studies have been restricted to a small geographical area excepting the epidemiological data from France which also shows a wide variation in prevalence depending on geographical location [29, 31, 32] . Further research should consider the influence of disease severity on the diagnosed prevalence rate and its potentially confounding effect on our observations with respect to sex, socioeconomic status and geographical location.
Comparison with existing literature
UK (the health authority with the highest crude prevalence of HHT) estimates a prevalence of 1.9 per 10,000 and would equate to at least 11,800 cases of HHT in a population of 62.3 million in 2010 [35] . The lower diagnostic rate of HHT in males and those from less affluent social backgrounds suggests a sociological (or alternatively a biological role) in the presentation of HHT, while the previously unreported regional differences is an observation that requires validation in other datasets. Future research would ideally draw on a national rare disease database with integrated clinical information and genetic samples allowing greater understanding of the presentation of the disease, the genotype-phenotype relationship in HHT and the influences upon it of moderator genes and external environmental factors. 
